Search Clinical Trials
Sponsor Condition of Interest |
---|
Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)
University of Michigan
Cardiac Arrest, Out-Of-Hospital
Hypothermia, Induced
Hypoxia-Ischemia, Brain
This is a multicenter trial to establish the efficacy of cooling and the optimal duration
of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac
arrest.
The study team hypothesizes that longer durations of cooling may improve either the
proportion of children that... expand
This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest. The study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome. Type: Interventional Start Date: Aug 2022 |
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib...
BeiGene
Relapsed/Refractory Multiple Myeloma
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in
combination with dexamethasone and carfilzomib intravenously across two cohorts with a
monotherapy component as well. expand
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well. Type: Interventional Start Date: Sep 2021 |
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid...
Xilio Development, Inc.
Advanced Solid Tumor
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate
the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart
(XTX101) and atezolizumab combination therapy in patients with advanced solid tumors. expand
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors. Type: Interventional Start Date: Sep 2021 |
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Massachusetts General Hospital
Benign Neoplasm
Malignant Neoplasm
In this research study we want to learn more about the use of indocyanine green (ICG)
during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that
is used in medical diagnostics. We want to determine if ICG-guided tumor resection is
more effective in obtaining negative... expand
In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival. Type: Interventional Start Date: May 2022 |
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
Biodesix, Inc.
Nodule Solitary Pulmonary
Non-small Cell Carcinoma
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical
management of newly identified solid lung nodules assessed as low to moderate risk of
cancer. expand
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer. Type: Observational Start Date: Dec 2020 |
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed...
Children's Oncology Group
B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma
Central Nervous System Leukemia
Mixed Phenotype Acute Leukemia
Testicular Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction
chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL)
improves outcomes. This trial also studies the outcomes of patients with mixed phenotype
acute leukemia (MPAL), and B-lymphoblastic... expand
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy. Type: Interventional Start Date: Oct 2019 |
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib...
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute
Refractory AML
Relapsed Adult AML
Myelodysplastic Syndrome With Excess Blasts-2
Chronic Myelomonocytic Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of
tuspetinib to be used in future studies in study participants diagnosed with acute
myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2
(MDS-IB2), or chronic myelomonocytic leukemia (CMML)... expand
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study. Type: Interventional Start Date: Mar 2019 |
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Dana-Farber Cancer Institute
Multiple Myeloma
The PROMISE Study aims to establish a prospective cohort of individuals with precursor
conditions to multiple myeloma, such as monoclonal gammopathy of undetermined
significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients
as a means to identify risk factors for progression... expand
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma. Type: Observational Start Date: Oct 2018 |
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Seagen Inc.
Colorectal Neoplasms
Carcinoma, Non-Small-Cell Lung
Exocrine Pancreatic Cancer
Carcinoma, Squamous Cell of Head and Neck
This trial will study tisotumab vedotin to find out whether it is an effective treatment
alone or with other anticancer drugs for certain solid tumors and what side effects
(unwanted effects) may occur. There are seven parts to this study.
- In Part A, the treatment will be given to participants... expand
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. - In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). - In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. - In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. - In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: - Pembrolizumab or, - Pembrolizumab and carboplatin, or - Pembrolizumab and cisplatin - In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. - In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. - In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin. Type: Interventional Start Date: Jun 2018 |
Pyruvate Kinase Deficiency Global Longitudinal Registry
Agios Pharmaceuticals, Inc.
Pyruvate Kinase Deficiency
This study is an observational (ie, noninterventional), longitudinal, multicenter, global
registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic
hemolytic anemia.
This Registry will be open for enrollment for 7 years and all enrolled participants will
be followed prospectively... expand
This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia. This Registry will be open for enrollment for 7 years and all enrolled participants will be followed prospectively for a minimum of 2 years, and up to 9 years. Data will be collected from participating Registry Physicians, participants, and, where appropriate, parents/guardians who have provided informed consent or assent (where relevant) and authorization pursuant to applicable laws and regulations. Data should include demographic, clinical, and treatment data; and other data of relevance to the management of patients with PK deficiency. Annual chart review and data entry are expected in order to enhance longitudinal understanding of PK deficiency; however, no specific protocol schedule of assessment is required by this Registry protocol. Type: Observational [Patient Registry] Start Date: Apr 2018 |
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Dana-Farber Cancer Institute
Malignant Glioma of Brain
Astrocytoma
Malignant Astrocytoma
Oligodendroglioma
Anaplastic Oligodendroglioma of Brain (Diagnosis)
This research study is evaluating an investigational drug, an oncolytic virus called
rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety
of an investigational drug and also tries to define the appropriate dose of the
investigational drug as a possible treatment... expand
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor. Type: Interventional Start Date: Jul 2017 |
Study of Kidney Tumors in Younger Patients
Children's Oncology Group
Adult Cystic Nephroma
Anaplastic Kidney Wilms Tumor
Angiolipoma
Cellular Congenital Mesoblastic Nephroma
Classic Congenital Mesoblastic Nephroma
This research trial studies kidney tumors in younger patients. Collecting and storing
samples of tumor tissue, blood, and urine from patients with cancer to study in the
laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid
(DNA) and identify biomarkers related to... expand
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. Type: Observational Start Date: Feb 2006 |
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene...
Tyra Biosciences, Inc
Locally Advanced Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
Solid Tumor
Metastatic Cholangiocarcinoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK),
and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene
alterations, including unresectable locally advanced/metastatic intrahepatic
cholangiocarcinoma and other advanced solid tumors. expand
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors. Type: Interventional Start Date: Nov 2023 |
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia...
Sanofi
Hemophilia A
This is a prospective, observational, multi-center longitudinal cohort study to describe
the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in
patients with hemophilia A treated per standard of care in the US and Japan.
Patients will be enrolled in the study after the... expand
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating physician independently from the decision to include patients in the study. No study medication is provided. The data related to efanesoctocog alfa effectiveness, safety and usage will be collected prospectively during routine visits (expected annual/semi-annual visits) for up to 5 years following enrollment /treatment initiation. Type: Observational Start Date: Jun 2023 |
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Abcuro, Inc.
T-cell Large Granular Lymphocytic Leukemia
An open label, ascending dose study for adult subjects with T-cell Large Granular
Lymphocytic Leukemia (T-LGLL) expand
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL) Type: Interventional Start Date: Sep 2022 |
Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD
Massachusetts General Hospital
Obsessive-Compulsive Disorder
The investigators want to learn more about how human beings learn not to fear and the
impact of changing the fear network in the brain using transcranial Direct Current
Stimulation (tDCS) in individuals with obsessive compulsive disorder (OCD). The
investigators hope this study will help us understand... expand
The investigators want to learn more about how human beings learn not to fear and the impact of changing the fear network in the brain using transcranial Direct Current Stimulation (tDCS) in individuals with obsessive compulsive disorder (OCD). The investigators hope this study will help us understand how future treatments can help patients with OCD better control unwanted fear. Type: Interventional Start Date: Sep 2022 |
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Mersana Therapeutics
HER2-positive Breast Cancer
HER2-positive Gastric Cancer
HER2-positive Non-Small Cell Lung Cancer
HER2-positive Colorectal Cancer
HER2-positive Tumors
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2. expand
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2. Type: Interventional Start Date: Jan 2023 |
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
Massachusetts General Hospital
Interstitial Lung Disease
The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen
deposition in early interstitial lung disease. expand
The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen deposition in early interstitial lung disease. Type: Interventional Start Date: Sep 2022 |
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants...
Arcus Biosciences, Inc.
Gastrointestinal Tract Malignancies
The purpose of this study is to evaluate the safety and preliminary clinical activity of
treatment combinations with and without chemotherapy in participants with locally
advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma.
Chemotherapy will consist of FOLFOX (oxaliplatin,... expand
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil). Type: Interventional Start Date: Jun 2022 |
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With...
Amryt Pharma
Partial Lipodystrophy
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily
SC metreleptin in subjects with Partial Lipodystrophy. expand
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy. Type: Interventional Start Date: Dec 2021 |
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)
Sanofi
Transplant Rejection
Primary Objectives:
- Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR
- Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR
Secondary Objectives:
- To assess the overall efficacy of BIVV020 in prevention or treatment of AMR
- To characterize... expand
Primary Objectives: - Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR - Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: - To assess the overall efficacy of BIVV020 in prevention or treatment of AMR - To characterize the safety and tolerability of BIVV020 in kidney transplant participants - To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants - To evaluate the immunogenicity of BIVV020 Type: Interventional Start Date: Jun 2022 |
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
ITB-Med LLC
Kidney Transplantation
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in
living donor renal transplant recipients expand
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients Type: Interventional Start Date: Dec 2022 |
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
Massachusetts General Hospital
Progressive Supranuclear Palsy
Parkinson Disease
MSA - Multiple System Atrophy
This is a single-arm, longitudinal, observational study on the use of wearable sensors
and digital health technology to measure fall frequency and motor, speech, and cognitive
function in patients with PSP over the course of approximately one year. Participants
will perform supervised remote assessments... expand
This is a single-arm, longitudinal, observational study on the use of wearable sensors and digital health technology to measure fall frequency and motor, speech, and cognitive function in patients with PSP over the course of approximately one year. Participants will perform supervised remote assessments monthly and in-person assessments approximately every 6 months. Type: Observational Start Date: May 2021 |
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Indiana University
Early Onset Alzheimer Disease
Alzheimer Disease
Mild Cognitive Impairment
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized,
natural history, non-treatment study designed to look at disease progression in
individuals with early onset cognitive impairment. Clinical, cognitive, imaging,
biomarker, and genetic characteristics will be assessed... expand
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants. Type: Observational Start Date: Apr 2018 |
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving...
Novartis Pharmaceuticals
Advanced Solid Tumors Which Are cMET-dependent
The purpose of this study is to assess long-term safety and provide continued study
treatment access to eligible participants who are judged by the Investigator to benefit
from continued treatment with capmatinib monotherapy or in combination with other
treatments or with the combination treatment... expand
The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study Type: Interventional Start Date: Jul 2017 |
- Previous
- Next